Industry analyst GlobalData has released research indicating that rapid growth in the graft versus host disease (GvHD) market is expected in the coming years.
Expansion in the market, which is expected to hit a compound annual growth rate (CAGR) of 8.3% from 2018 to 2028, will be driven by the launch of approved therapies demanding higher prices.
Novel products will likely garner significantly higher prices than the currently used off-label options, such as the current standard of care, corticosteroids.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze